Sep 14, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S. Food and Drug Administration for its phase 1/2a first in-human clinical trial evaluating CYB003. This milestone achievement marks the industry’s first-ever novel psilocybin analog to enter clinical development; the company has started recruiting patients and expects to provide an interim pharmacokinetic and safety readout later this year,” a recent article reads. “We are extremely pleased to advance CYB003 into clinical development so quickly,” Cybin CEO Doug Drysdale is quoted as saying. “This phase 1/2a trial represents the first time that a psilocybin analog will be evaluated in humans for the treatment of MDD and is the key next step toward our ultimate goal of providing a new and effective treatment for people suffering from mental health conditions.”
To view the full article, visit https://ibn.fm/uUn2L
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Dangerous supercells are barreling towards eastern Australia, bringing storms, monster hail, and possible tornadoes.
Hong Kong will launch a 30,000-place youth employment and internship programme in the first quarter of 2027. Before applications open, the government should decide what it is buying: a temporary increase in headcount or a durable increase in professional capability. The distinction matters because the entry-level labour market is already changing. According to an annual survey by Baptist University, the starting-pay advantage of bachelor’s degree holders over sub-degree graduates narrowed by 17...
A new government initiative is placing nervous early-career educators into high-needs schools to challenge deep-rooted stigmas.
Almost 50 people have been recruited by the Victorian Electoral Commission to patrol polling booths from the start of early voting.
This article was first published on November 4, 2011. China a step closer to building its own space station by Stephen Chen Encouraged by yesterday (November 3, 2011) morning’s historic rendezvous and docking of the Shenzhou VIII spacecraft, Chinese authorities said construction of a space station will begin as soon as 2013. “We will do two more rendezvous and docking flights next year,” said Wu Ping (武平), spokeswoman for the manned space programme, at a press conference in Beijing yesterday....
An Adelaide council is under fire after choosing to spend $50,000 on building a single drinking fountain.
Most families have already cut back everywhere they can following a string of painful rate hikes, here are some simple hacks to claw back some cash.
Rochelle Courtenay tells CityChats about how a confronting statistic led her to starting her national charity, Share the Dignity.
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...
Amelia Luca spent years watching “what I eat in a day” and pro-anorexia social media content. Six years later, she’s taking Meta to court.
Beijing says it will introduce extra measures, as needed, to bolster Hong Kong as an international financial centre, with Vice-Premier He Lifeng pledging continued support in a speech on Tuesday. Delivering a keynote speech at the opening of the 2026 Global Financial Leaders’ Investment Summit in Hong Kong via video link, He said finance was the most important leg of the city’s “four centres and one highland” agenda and stressed that using the advantages of the “one country, two systems”...
Travellers flying from Hangzhou or Wuhan to overseas destinations via Hong Kong on different airlines can have their baggage checked through to the final destination under a newly launched service that aims to streamline connections between mainland Chinese cities and other countries. Under the new one-stop service that launched on Tuesday, travellers departing from Hangzhou Xiaoshan International Airport or Wuhan Tianhe International Airport will not need to check in their baggage again when...
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.